Barclays Issues a Buy Rating on Intuitive SurgicalBy Ryan Adsit
In a report issued on April 17, Matthew Taylor from Barclays maintained a Buy rating on Intuitive Surgical (NASDAQ: ISRG), with a price target of $830. The company’s shares closed yesterday at $759.34.
According to TipRanks.com, Taylor is a 5-star analyst with an average return of 9.1% and a 71.7% success rate. Taylor covers the Healthcare sector, focusing on stocks such as Boston Scientific Corp, Zimmer Biomet Holdings, and Baxter International.
Intuitive Surgical has an analyst consensus of Moderate Buy, with a price target consensus of $762.50.
Based on Intuitive Surgical’s latest earnings report for the quarter ending December 31, the company posted quarterly revenue of $757 million and quarterly net profit of $204 million. In comparison, last year the company earned revenue of $594 million and had a net profit of $136 million.
Based on the recent corporate insider activity of 65 insiders, corporate insider sentiment is negative on the stock. Last month, Lonnie Smith, a Director at ISRG sold 35 shares for a total of $25,767.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Intuitive Surgical, Inc. engages in the development, manufacture, and marketing of da Vinci Surgical Systems, and related instruments and accessories for invasive surgery. The company was founded by Frederic H. Moll, John Gordon Freund, and Robert G. Younge in November 1995 and is headquartered in Sunnyvale, CA.